Liftstream is an executive search recruitment company in the life sciences sector
Prosensa, Sarepta, PTC, Summit and DART all contribute to the ubiquity of news in Duchenne
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Amsterdam Biotech, Ataluren, Charity, clinical, DART Therapeutics, DMD, Drisapersen, Duchenne Muscular Dystrophy, Eteplirsen, FDA, Gene Williams, Glynn Edwards, GSK, GSK/Prosensa, HT-100, IPO, Market Access, NASDAQ, Netherlands, Orphan drugs, Oxford Biotech, phase II studies, Priority Review, Prosensa, PTC Therapeutics, Rare Disease, regulatory affairs, research and development, Sarepta Therapeutics, Save our Sons, SMT C1100, Summit plc, UK, USA, Utrophin, utrophin modulation
2 Comments
Sarepta’s hopes high for first Duchenne (DMD) therapy
Authored by James Sheppard
Posted in Orphan Drugs and Rare Diseases
Tagged AVI Biopharma, AVI-7100, Department of Defense, DMD, Duchenne Muscular Dystrophy, Ebola, EMEA, Eteplirsen, exon skipping, FDA, Infectious Disease, Influenza, Liftstream Rare Disease Day, Marburg Virus, NIH Clinical Center in Bethesda, Phase II Trials, PMO Chemistry, Rare Disease Day 2013, RDD13, Sarepta Therapeutics, UCL, University College London, USA
Leave a comment